This site is intended for healthcare professionals

Welcome to InterACT Podcasts. A series developed by AstraZeneca, where we will be exploring the inequalities of care for people living with long-term conditions.

For more CPD-accredited education, visit

InterACT Medical Education is a series of non-promotional educational resources created and funded by AstraZeneca.

Head of UK External Scientific Engagement

Medical Information Specialist

A renewed focus on symptom awareness for ovarian cancer in primary care (Content from AstraZeneca)

Recent data publications have highlighted the health inequalities that exist for ovarian cancer in the UK. In this episode, Dr Tracie Miles discusses the importance of symptom recognition for ovarian cancer in primary care. Dr Miles is a Gynaecological Cancer Nurse Specialist, Genomics (Practitioner) based at Royal United Hospital Bath NHS Foundation Trust.

Recent data publications have highlighted the health inequalities that exist for ovarian cancer in the UK. In this episode, Dr Tracie Miles discusses the importance of symptom recognition for ovarian cancer in primary care. Dr Miles is a Gynaecological Cancer Nurse Specialist, Genomics (Practitioner) based at Royal United Hospital Bath NHS Foundation Trust.

Dr Tracie Miles would like her take home messages to be:

  1. National variations around the diagnosis and management of ovarian cancer exist, with no screening programme on the horizon.
  2. Where possible, get to know your local gynaecological cancer nurse specialist within secondary care.
  3. Understand that there is a serious need for ovarian cancer. Remember that suspicious symptoms require a speedy referral.

 

Useful links

 

References

  1. National Cancer Registration and Analysis Service. Ovarian Cancer Audit Feasibility Pilot: Outputs. Available at: http://www.ncin.org.uk/cancer_type_and_topic_specific_work/cancer_type_specific_work/
    gynaecological_cancer/gynaecological_cancer_hub/ovarian_cancer_audit_feasibility_pilot_outputs
    (accessed October 2021)
  2. Menon U, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021;397(10290):2182-2193. doi: 10.1016/S0140-6736(21)00731-5.
  3. The Eve Appeal. UKCTOCS. 2021. Available at: https://eveappeal.org.uk/our-research/our-research-programmes/ukctocs/ (accessed October 2021)
  4. MRC Clinical Trials Unit at UCL. UKCTOCS. 2021. Available at: https://www.ctu.mrc.ac.uk/studies/all-studies/u/ukctocs/ (accessed October 2021)
  5. Cancer Research UK. A trial looking at screening the general population for ovarian cancer (UKCTOCS). 2021. Available at: https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-at-screening-the-general-population-for-ovarian-cancer#undefined (accessed October 2021)
  6. NICE. 2021. Ovarian cancer – NICE Pathways. Available at: https://pathways.nice.org.uk/pathways/ovarian-cancer#content=view-node%3Anodes-ovarian-cancer-services (accessed October 2021)

Recent data publications have highlighted the health inequalities that exist for ovarian cancer in the UK. In this episode, Dr Tracie Miles discusses the importance of symptom recognition for ovarian cancer in primary care. Dr Miles is a Gynaecological Cancer Nurse Specialist, Genomics (Practitioner) based at Royal United Hospital Bath NHS Foundation Trust.

Dr Tracie Miles would like her take home messages to be:

  1. National variations around the diagnosis and management of ovarian cancer exist, with no screening programme on the horizon.
  2. Where possible, get to know your local gynaecological cancer nurse specialist within secondary care.
  3. Understand that there is a serious need for ovarian cancer. Remember that suspicious symptoms require a speedy referral.

 

Useful links

 

References

  1. National Cancer Registration and Analysis Service. Ovarian Cancer Audit Feasibility Pilot: Outputs. Available at: http://www.ncin.org.uk/cancer_type_and_topic_specific_work/cancer_type_specific_work/
    gynaecological_cancer/gynaecological_cancer_hub/ovarian_cancer_audit_feasibility_pilot_outputs
    (accessed October 2021)
  2. Menon U, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021;397(10290):2182-2193. doi: 10.1016/S0140-6736(21)00731-5.
  3. The Eve Appeal. UKCTOCS. 2021. Available at: https://eveappeal.org.uk/our-research/our-research-programmes/ukctocs/ (accessed October 2021)
  4. MRC Clinical Trials Unit at UCL. UKCTOCS. 2021. Available at: https://www.ctu.mrc.ac.uk/studies/all-studies/u/ukctocs/ (accessed October 2021)
  5. Cancer Research UK. A trial looking at screening the general population for ovarian cancer (UKCTOCS). 2021. Available at: https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-at-screening-the-general-population-for-ovarian-cancer#undefined (accessed October 2021)
  6. NICE. 2021. Ovarian cancer – NICE Pathways. Available at: https://pathways.nice.org.uk/pathways/ovarian-cancer#content=view-node%3Anodes-ovarian-cancer-services (accessed October 2021)

Adverse events should be reported. Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca by
visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.

GB-31877 | October 2021

GPnotebook has had no input into the content of InterACT Podcast episodes.

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.